Clinical trial
Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular…
NCT00417430 · The Center for Rheumatic Disease, Allergy, & Immunology, Other · Completed
Key facts
| NCT number | NCT00417430 |
|---|---|
| Title | Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies |
| Official title | Phase II Study of Efficacy of ICI 182,780 (Faslodex) in the Treatment of Systemic Lupus Erythematosus: Clinical, Serologic, Molecular |
| Lead sponsor | The Center for Rheumatic Disease, Allergy, & Immunology, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Systemic Lupus Erythematosus |
| Intervention type | Drug |
| Interventions | ICI 182, 780 (Faslodex) |
| Enrollment | 20 |
| Start date | Sep 1, 2004 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Jan 1, 2007 |
| Last update posted | Sep 22, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: